Search
siponimod (Mayzent)
Indications:
- treatment of adults with relapsing forms of multiple sclerosis, including active secondary progressive multiple sclerosis [1]
Contraindication:
- pregnancy
Dosage:
- oral
Monitor:
- prior to initiation of therapy
- complete blood count
- liver function tests
- blood pressure during treatment
Adverse effects:
- most common
- headache
- hypertension
- abnormal liver function tests
- other
- risk of infections
- macular edema
- decline in lung function
- transient bradycardia
- posterior reversible encephalopathy syndrome
Notes:
- must be dispensed with a patient Medication Guide that describes important information about uses & risks
- FDA approval granted to Novartis March 2019
General
neurologic agent
Database Correlations
PUBCHEM cid=44599207
References
- FDA News Release. March 26, 2019
FDA approves new oral drug to treat multiple sclerosis.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634469.htm